Research and Development Archives – Page 5 of 8

Investment in HIV Research Profoundly Benefits the COVID-19 Response

December 2, 2020
Dorrit Walsh

This policy brief discusses how investment in HIV research has profoundly benefitted the COVID-19 response, and advocates that continued financial support for HIV science can both ensure progress on COVID-19 and avoid losing ground—and lives—in the fight to end the HIV epidemic.

TB Research Investments Provide Returns in Combating Both TB and COVID-19

September 4, 2020
Dorrit Walsh

As the COVID-19 pandemic continues to radically shift the global health landscape and alter government/donor commitments, TAG has released this timely brief to explore the impact of COVID-19 on TB research and development (R&D), and how tools, concepts, capacity, and…

Ensuring Universal Access to COVID-19 Diagnosis, Treatment and Prevention

July 27, 2020
Dorrit Walsh

TAG and the Center for Economic and Social Rights produced this joint publication, as part of CESR’s COVID-19 “Recovering Rights” series of briefs.

Treatment Action Group Statement on New HIV Remission Case Report at AIDS2020

July 8, 2020
Dorrit Walsh

Yesterday, a widely reported presentation by Ricardo Diaz at the ongoing virtual International AIDS Conference (AIDS2020) disclosed that one out of 30 total participants in an HIV cure-related research trial conducted in Brazil has not experienced an HIV viral load rebound for a little over a year (64.7 weeks) after interrupting antiretroviral therapy (ART).

Global Health and Human Rights Organizations Say U.S. Withdrawal from WHO Is Reckless Act That Could Delay Americans’ Access to COVID-19 Solutions and Prolong Global Pandemic

July 7, 2020
Dorrit Walsh

AVAC, Health GAP and the Treatment Action Group (TAG) strongly condemn the Trump Administration’s withdrawal from the World Health Organization (WHO).

AVAC and TAG Statement on Ethical Conduct of SARS-CoV-2 Vaccine Challenge Studies

May 7, 2020
Dorrit Walsh

The COVID-19 pandemic is a global health emergency that may demand new, safe, and expedited ways of conducting ethical research to find the solutions we need, including a safe and effective vaccine.

Treatment Action Group Statement on BCG Vaccine and COVID-19

April 9, 2020
Dorrit Walsh

Treatment Action Group (TAG) cautions that widespread media reports that the baccille Calmette–Guérin (BCG) vaccine may be protective against COVID-19 need to be read with caution.

The Future of Biomedical HIV Prevention Trials: Researcher Viewpoints and Community Survey

March 6, 2020
Dorrit Walsh

This report aims to make more accessible to community advocates discussions around ethical conduct of biomedical prevention trials in the era of PrEP. In early 2019, TAG, along with Black AIDS Institute and the HIV Vaccine Trials Network developed an…

Treatment Action Group Statement on the HVTN 702 HIV Vaccine Trial Results

February 3, 2020
Dorrit Walsh

Treatment Action Group acknowledges with profound disappointment today’s announcement that the HIV Vaccine Trials Network HVTN 702 study did not demonstrate efficacy in preventing HIV acquisition.

Cover of Tuberculosis Research Funding Trends 2005-2018

2019 Report on TB Research Funding Trends

December 10, 2019
Dorrit Walsh

TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2018 and analyzes trends in funding since 2005.